Credits Available: 4.25 AMA PRA Category 1 Credits™, 4.25 ANCC Contact Hours, 4.25 ACPE

Description: This dynamic curriculum, detailed by a specialty center clinician, explores each of the CD 19-directed CAR T-cell therapies available for the treatment of DLBCL; solutions to referral and logistic challenges; in-depth early and late toxicity management in CAR T-cell treatment; and the delivery of goal-concordant care using shared decision-making strategies. A challenging real-world case scenario discussion within each Gather-ed group highlights critical decision points, key challenges, and opportunities to incorporate collective insights.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Pharmacist, Physician Assistant, Nurse, Pharmacy Director
Target Specialties: Hematology, Hematology/Oncology, Oncology

Mazyar Shadman

Fred Hutchinson Cancer Center
Medical Director

Dr. Mazyar Shadman is a blood cancer specialist who focuses on lymphoid malignancies. He is involved in clinical research using novel therapeutic agents for lymphoma and chronic lymphocytic leukemia, or CLL, as well as immunotherapy (specifically CAR T cell therapy) for lymphoid neoplasms and blood stem cell transplant for hematologic malignancies. His goal is to identify the best treatment sequence or combination for patients with high-risk lymphoma and CLL.